Orexo announces successful completion of rights issue providing gross proceeds of about SEK 250 million
Read more about Orexo Rights Issue at:http://www.orexo.com/en/Investor-Relations/Rights-issue---Important-Information/ For further information, contact:Anders Lundström, President and CEO of OrexoTel: +46 (0)70-667 22 66E-mail: anders.lundstrom@orexo.com About OrexoOrexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo’s registered products are Abstral® for the treatment of break through